The mechanism of these phenomena might be clonal selection under therapeutic pressure: myeloma cells with high BCMA expression are eliminated by BCMA CAR-T cells, while low BCMA expression cells are selected to survive. Here, TNFRSF17 is linked to plasma cell myeloma.